Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics
05/10/24 • 22 min
Previous Episode
Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?
Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?
Next Episode
Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents
Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/peervoice-clinical-pharmacology-audio-307161/christian-r%c3%a9cher-md-phd-practical-considerations-for-flt3-inhibitors-i-51350864"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to christian récher, md, phd - practical considerations for flt3 inhibitors in acute myeloid leukaemia: optimising our first-line approaches with current and novel therapeutics on goodpods" style="width: 225px" /> </a>
Copy